3DLS.F | PASK

General Structure Information 3dls PASK crystal structure of human pas kinase bound to adp 2.3Å AUTH C.K.KIKANI,S.A.ANTONYSAMY,J.B.BONANNO,R.ROMERO,F.F.ZHANG,AUTH 2 M.RUSSELL,T.GHEYI,M.IIZUKA,S.EMTAGE,J.M.SAUDER,B.E.TURK,AUTH 3 S.K.BURLEY,J.RUTTERTITL STRUCTURAL BASES OF PAS DOMAIN-REGULATED KINASE (PASK)TITL 2 ACTIVATION IN THE ABSENCE OF ACTIVATION LOOPTITL 3 PHOSPHORYLATION.REF J.BIOL.CHEM. V. 285 41034 2010REFN ISSN 0021-9258PMID 20943661DOI 10.1074/JBC.M110.157594 Variant Set Distributions Mapped Variants

See Details
2HW6.A | MKNK1

General Structure Information 2hw6 MKNK1 crystal structure of mnk1 catalytic domain 2.5Å AUTH R.JAUCH,M.K.CHO,C.NETTER,K.SCHREITER,B.AICHER,AUTH 2 M.ZWECKSTETTER,M.C.WAHLTITL MITOGEN-ACTIVATED PROTEIN KINASES INTERACTING KINASES ARETITL 2 AUTOINHIBITED BY A REPROGRAMMED ACTIVATION SEGMENT.REF EMBO J. V. 25 4020 2006REFN ISSN 0261-4189PMID 16917500DOI 10.1038/SJ.EMBOJ.7601285 Variant Set Distributions Mapped Variants

See Details
3F7G.B | BIRC7

General Structure Information 3f7g BIRC7 structure of the bir domain from ml-iap bound to a peptidomimetic 2.3Å AUTH F.COHEN,B.ALICKE,L.O.ELLIOTT,J.A.FLYGARE,T.GONCHAROV,AUTH 2 S.F.KETELTAS,M.C.FRANKLIN,S.FRANKOVITZ,J.P.STEPHAN,V.TSUI,AUTH 3 D.VUCIC,H.WONG,W.J.FAIRBROTHERTITL ORALLY BIOAVAILABLE ANTAGONISTS OF INHIBITOR OF APOPTOSISTITL 2 PROTEINS BASED ON AN AZABICYCLOOCTANE SCAFFOLDREF J.MED.CHEM. V. 52 1723 2009REFN ISSN 0022-2623PMID 19228017DOI 10.1021/JM801450C Variant Set Distributions Mapped Variants

See Details
2WEK.A | ZADH2

General Structure Information 2wek ZADH2 crystal structure of the human mgc45594 gene product in complex with diclofenac 1.9Å AUTH N.SHAFQAT,W.W.YUE,F.NIESEN,U.OPPERMANNTITL CRYSTAL STRUCTURE OF THE HUMAN MGC45594 GENE PRODUCT INTITL 2 COMPLEX WITH DICLOFENACREF TO BE PUBLISHEDREFN Variant Set Distributions Ripley’s K Analysis Plots Variant Set Comparisons Pathogenic Proximity Analysis Mapped Variants

See Details
3T3S.E | CYP2A13

General Structure Information 3t3s CYP2A13 human cytochrome p450 2a13 in complex with pilocarpine 3.0Å AUTH N.M.DEVORE,K.M.MENEELY,A.G.BART,E.S.STEPHENS,K.P.BATTAILE,AUTH 2 E.E.SCOTTTITL STRUCTURAL COMPARISON OF CYTOCHROMES P450 2A6, 2A13, AND 2E1TITL 2 WITH PILOCARPINE.REF FEBS J. V. 279 1621 2012REFN ISSN 1742-464XPMID 22051186DOI 10.1111/J.1742-4658.2011.08412.X Variant Set Distributions Ripley’s K Analysis Plots Variant Set Comparisons Pathogenic Proximity Analysis Mapped Variants

See Details
3CZH.A | CYP2R1

General Structure Information 3czh CYP2R1 crystal structure of cyp2r1 in complex with vitamin d2 2.3Å AUTH N.V.STRUSHKEVICH,W.TEMPEL,A.A.GILEP,P.LOPPNAU,AUTH 2 C.H.ARROWSMITH,A.M.EDWARDS,C.BOUNTRA,M.WILKSTROM,AUTH 3 A.BOCHKAREV,H.PARKTITL CRYSTAL STRUCTURE OF CYP2R1 IN COMPLEX WITHTITL 2 VITAMIN D2.REF TO BE PUBLISHEDREFN Variant Set Distributions Ripley’s K Analysis Plots Variant Set Comparisons Mapped Variants

See Details
3GC9.A | MAPK11

General Structure Information 3gc9 MAPK11 the structure of p38beta c119s, c162s in complex with a dihydroquinazolinone inhibitor 2.05Å AUTH S.B.PATEL,P.M.CAMERON,S.J.OKEEFE,B.FRANTZ-WATTLEY,AUTH 2 J.THOMPSON,E.A.ONEILL,T.TENNIS,L.LIU,J.W.BECKER,G.SCAPINTITL THE THREE-DIMENSIONAL STRUCTURE OF MAP KINASE P38BETA:TITL 2 DIFFERENT FEATURES OF THE ATP-BINDING SITE IN P38BETATITL 3 COMPARED WITH P38ALPHA.REF ACTA CRYSTALLOGR.,SECT.D V. 65 777 2009REFN ISSN 0907-4449PMID 19622861DOI 10.1107/S090744490901600X Variant Set Distributions […]

See Details
1XKT.A | FASN

General Structure Information 1xkt FASN human fatty acid synthase: structure and substrate selectivity of the thioesterase domain 2.6Å AUTH B.CHAKRAVARTY,Z.GU,S.S.CHIRALA,S.J.WAKIL,AUTH 2 F.A.QUIOCHOTITL HUMAN FATTY ACID SYNTHASE: STRUCTURE AND SUBSTRATETITL 2 SELECTIVITY OF THE THIOESTERASE DOMAIN.REF PROC.NATL.ACAD.SCI.USA V. 101 15567 2004REFN ISSN 0027-8424PMID 15507492DOI 10.1073/PNAS.0406901101 Variant Set Distributions Mapped Variants

See Details
4BCJ.A | CDK9

General Structure Information 4bcj CDK9 structure of cdk9 in complex with cyclin t and a 2-amino-4- heteroaryl-pyrimidine inhibitor 3.16Å AUTH A.J.HOLE,S.BAUMLI,H.SHAO,S.SHI,C.PEPPER,P.M.FISCHER,S.WANG,AUTH 2 J.A.ENDICOTT,M.E.M.NOBLETITL COMPARATIVE STRUCTURAL AND FUNCTIONAL STUDIES OFTITL 2 4-(THIAZOL- 5-YL)-2-(PHENYLAMINO)PYRIMIDINE-5-CARBONITRILETITL 3 CDK9 INHIBITORS SUGGEST THE BASIS FOR ISOTYPE SELECTIVITY.REF J.MED.CHEM. V. 56 660 2013REFN ISSN 0022-2623PMID 23252711DOI 10.1021/JM301495V Variant Set Distributions Mapped Variants

See Details
4BKT.I | VHL

General Structure Information 4bkt VHL von hippel lindau protein:elonginb:elonginc complex, in complex with (2s,4r)-n-methyl-1-[2-(3-methyl-1,2-oxazol-5-yl)ethanoyl]-4- oxidanyl-pyrrolidine-2-carboxamide 2.35Å AUTH D.M.DIAS,I.VAN MOLLE,M.G.J.BAUD,C.GALDEANO,C.F.G.C.GERALDES,AUTH 2 A.CIULLITITL IS NMR FRAGMENT SCREENING FINE-TUNED TO ASSESS DRUGGABILITYTITL 2 OF PROTEIN-PROTEIN INTERACTIONS?REF ACS MED.CHEM.LETT. V. 5 23 2014REFN ISSN 1948-5875PMID 24436777DOI 10.1021/ML400296C Variant Set Distributions Ripley’s K Analysis Plots Variant Set Comparisons Pathogenic Proximity […]

See Details